Abstract:6094 Background: Cancers deficient in homologous recombination (HR) exhibit synthetic lethality when treated with poly (ADP-ribose) polymerase (PARP) inhibitors and may be more sensitive to platinum based therapies. While BRCA1/2 mutations are uncommon in head and neck cancer (HNC), we hypothesized that other mechanisms of HR deficiency occur frequently. Methods: We employed three methods to determine homologous recombination deficiency (HRD): (1) HRD-score, (2) Large-scale chromosomal breaks (Popova et al), (3) BRCA-like CN profile (Schouten et al) using HNC TCGA and Chicago HNC Genomic cohort (CHGC) data. We furthermore screened for HR pathway mutations in both genomic cohorts. Single agent activity of three PARP inhibitors (veliparib (non-locking), olaparib and rucaparib (locking)) was evaluated in a panel of 10 HNC cell lines (colony formation, viability) and compared with a BRCA deficient breast cancer cell line. Immunofluorescent staining for γH2AX and RAD51 was performed. A gene signature of HRD deficiency was developed. Results: HR deficiency was present in 25% of HNC, and was largely concordant between all three methods (1. and 2. had the highest correlation), but were not related to BRCA1/2 mutations in HNC TCGA. BRCA1/2 mutations were rare (<1%) and of unclear significance. In a panel of HNC cell lines rucaparib showed the highest potency as a single agent with three cell lines exhibiting sensitivity (IC50: 7.0µM, 10.3µM and 11.7µM), comparable or superior to a BRCA deficient breast cancer cell line (IC50value: 8.9µM). Seven HNC cell lines were more resistant to single agent PARP inhibition. Foci formation of the HR marker RAD51 did not serve as a reliable biomarker in those cell lines, but our newly developed gene expression signature was applicable. Conclusions: In conclusion, we discover that HR-deficiency is present in 25% of HNC tumors, and benefit of single agent PARP inhibition is present in pre-clinical HNC models, despite the general absence of BRCA mutations in this tumor type. HRD-score is a candidate biomarker to identify patients that may benefit from PARP inhibition, including combinations with cytotoxic chemotherapies or radiation in the future.

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

PARP inhibitor resistance: the underlying mechanisms and clinical implications

Evaluation of Homologous Recombination Deficiency in Ovarian Cancer

Author Correction: the Bromodomain Containing Protein BRD-9 Orchestrates RAD51–RAD54 Complex Formation and Regulates Homologous Recombination-Mediated Repair

Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches

Antitumor Efficacy of PARP Inhibitors in Homologous Recombination Deficient Carcinomas

New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors

Correlation of Homologous Recombination Deficiency in Head and Neck Cancer with Sensitivity to Parp Inhibition

Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency

Clinical Homologous Recombination Repair Gene Reversion Analysis Identifies Mechanisms of Resistance to PARP Inhibitors and Platinum‐chemotherapy

A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer

Leveraging homologous recombination repair deficiency in sarcoma

Molecular Pathways: Targeting PARP in Cancer Treatment

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers

Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency

Advances and Perspectives of PARP Inhibitors